Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebicorvir extension study in chronic hepatitis B
NCT03780543Phase 2Terminated
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Dec 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of vebicorvir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Assembly Biosciences, Inc. Primary endpoint: Sustained Viral Response at 24 Weeks Off Treatment. Started Dec 2018; status: terminated.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03780543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780543.